Concord Healthcare Group (HKG:2453) said China's National Medical Products Administration approved a Registration Certificate for Medical Device for the proton therapy equipment by the company's supplier on Dec. 6, according to a Monday filing with the Hong Kong bourse.
The clinical trial of the proton therapy treatment was undertaken, after which the National Health Commission approved licensing the device to the company. Concord Healthcare Group said the proton therapy treatment will be available soon following completion of some preparations, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments